JP2013544788A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013544788A5 JP2013544788A5 JP2013534046A JP2013534046A JP2013544788A5 JP 2013544788 A5 JP2013544788 A5 JP 2013544788A5 JP 2013534046 A JP2013534046 A JP 2013534046A JP 2013534046 A JP2013534046 A JP 2013534046A JP 2013544788 A5 JP2013544788 A5 JP 2013544788A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- composition according
- influenza
- administration
- polymerase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 claims description 154
- 230000009385 viral infection Effects 0.000 claims description 54
- 208000036142 Viral infection Diseases 0.000 claims description 48
- 241000710772 Yellow fever virus Species 0.000 claims description 34
- 229940051021 yellow-fever virus Drugs 0.000 claims description 34
- 241000712431 Influenza A virus Species 0.000 claims description 33
- 241000713196 Influenza B virus Species 0.000 claims description 33
- 241000725619 Dengue virus Species 0.000 claims description 26
- 241000709661 Enterovirus Species 0.000 claims description 26
- 241000712079 Measles morbillivirus Species 0.000 claims description 26
- 241000710886 West Nile virus Species 0.000 claims description 26
- 241001115402 Ebolavirus Species 0.000 claims description 24
- 241001115401 Marburgvirus Species 0.000 claims description 24
- 239000003443 antiviral agent Substances 0.000 claims description 24
- 241001493065 dsRNA viruses Species 0.000 claims description 22
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 18
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 18
- 241000712908 Tacaribe mammarenavirus Species 0.000 claims description 18
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims description 18
- 241000701161 unidentified adenovirus Species 0.000 claims description 18
- 238000007918 intramuscular administration Methods 0.000 claims description 16
- 238000001990 intravenous administration Methods 0.000 claims description 16
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 claims description 16
- 229960001084 peramivir Drugs 0.000 claims description 16
- 241000315672 SARS coronavirus Species 0.000 claims description 12
- 230000003612 virological effect Effects 0.000 claims description 12
- 241000712892 Arenaviridae Species 0.000 claims description 10
- 241000711573 Coronaviridae Species 0.000 claims description 10
- 241000711950 Filoviridae Species 0.000 claims description 10
- 241000710781 Flaviviridae Species 0.000 claims description 10
- 241000712890 Junin mammarenavirus Species 0.000 claims description 10
- 241000712464 Orthomyxoviridae Species 0.000 claims description 10
- 241000711504 Paramyxoviridae Species 0.000 claims description 10
- 241000150350 Peribunyaviridae Species 0.000 claims description 10
- 241000709664 Picornaviridae Species 0.000 claims description 10
- 241000710924 Togaviridae Species 0.000 claims description 10
- 241001493160 California encephalitis virus Species 0.000 claims description 8
- 241000709687 Coxsackievirus Species 0.000 claims description 8
- 241000710945 Eastern equine encephalitis virus Species 0.000 claims description 8
- 241000991587 Enterovirus C Species 0.000 claims description 8
- 241000190708 Guanarito mammarenavirus Species 0.000 claims description 8
- 206010061598 Immunodeficiency Diseases 0.000 claims description 8
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 8
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 8
- QNRRHYPPQFELSF-CNYIRLTGSA-N Laninamivir Chemical compound OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O QNRRHYPPQFELSF-CNYIRLTGSA-N 0.000 claims description 8
- 206010023927 Lassa fever Diseases 0.000 claims description 8
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims description 8
- 241000712898 Machupo mammarenavirus Species 0.000 claims description 8
- 241000150452 Orthohantavirus Species 0.000 claims description 8
- 241000713124 Rift Valley fever virus Species 0.000 claims description 8
- 241000700647 Variola virus Species 0.000 claims description 8
- 241000710951 Western equine encephalitis virus Species 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 206010014599 encephalitis Diseases 0.000 claims description 8
- 208000006454 hepatitis Diseases 0.000 claims description 8
- 231100000283 hepatitis Toxicity 0.000 claims description 8
- 230000007813 immunodeficiency Effects 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 238000007912 intraperitoneal administration Methods 0.000 claims description 8
- 229950004244 laninamivir Drugs 0.000 claims description 8
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 8
- 229960003752 oseltamivir Drugs 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 229960001028 zanamivir Drugs 0.000 claims description 8
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims description 8
- 206010037660 Pyrexia Diseases 0.000 claims description 6
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 241000713126 Punta Toro virus Species 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 201000003486 coccidioidomycosis Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 description 93
- 241000282898 Sus scrofa Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39352210P | 2010-10-15 | 2010-10-15 | |
| US61/393,522 | 2010-10-15 | ||
| US201161492054P | 2011-06-01 | 2011-06-01 | |
| US61/492,054 | 2011-06-01 | ||
| PCT/US2011/056421 WO2012051570A1 (en) | 2010-10-15 | 2011-10-14 | Methods and compositions for inhibition of polymerase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016046875A Division JP2016135790A (ja) | 2010-10-15 | 2016-03-10 | ポリメラーゼの阻害のための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013544788A JP2013544788A (ja) | 2013-12-19 |
| JP2013544788A5 true JP2013544788A5 (enExample) | 2014-10-30 |
| JP5902698B2 JP5902698B2 (ja) | 2016-04-13 |
Family
ID=45938737
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013534046A Active JP5902698B2 (ja) | 2010-10-15 | 2011-10-14 | ポリメラーゼの阻害のための方法および組成物 |
| JP2016046875A Withdrawn JP2016135790A (ja) | 2010-10-15 | 2016-03-10 | ポリメラーゼの阻害のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016046875A Withdrawn JP2016135790A (ja) | 2010-10-15 | 2016-03-10 | ポリメラーゼの阻害のための方法および組成物 |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US20130331404A1 (enExample) |
| EP (3) | EP2898885B1 (enExample) |
| JP (2) | JP5902698B2 (enExample) |
| KR (1) | KR101850925B1 (enExample) |
| CN (1) | CN103429245B (enExample) |
| AU (2) | AU2011315902B2 (enExample) |
| BR (1) | BR112013009029B1 (enExample) |
| CA (1) | CA2813783C (enExample) |
| CY (1) | CY1119880T1 (enExample) |
| DK (2) | DK2898885T3 (enExample) |
| ES (2) | ES2536831T3 (enExample) |
| HR (2) | HRP20150487T1 (enExample) |
| HU (1) | HUE036387T2 (enExample) |
| IL (1) | IL225672B (enExample) |
| LT (1) | LT2898885T (enExample) |
| MX (1) | MX348759B (enExample) |
| PL (2) | PL2898885T3 (enExample) |
| PT (2) | PT2898885T (enExample) |
| RS (2) | RS54072B1 (enExample) |
| RU (3) | RU2599013C2 (enExample) |
| SI (2) | SI2627334T1 (enExample) |
| SM (2) | SMT201800064T1 (enExample) |
| WO (1) | WO2012051570A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009240630B2 (en) | 2008-04-23 | 2013-07-18 | Gilead Sciences, Inc. | Carba-nucleoside analogs for antiviral treatment |
| TWI483950B (zh) | 2009-09-21 | 2015-05-11 | Gilead Sciences Inc | 用於製備１’－取代碳核苷類似物之方法及中間物 |
| WO2012012465A1 (en) | 2010-07-19 | 2012-01-26 | Clarke, Michael, O'neil Hanrahan | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| PH12013500035A1 (en) | 2010-07-22 | 2013-03-11 | Gilead Sciences Inc | Methods and compounds for treating paramyxoviridae virus infections |
| EP2898885B1 (en) * | 2010-10-15 | 2017-11-22 | Biocryst Pharmaceuticals, Inc. | Pyrrolopyrimidine derivatives for use in the treatment of viral infections |
| AR090699A1 (es) * | 2012-04-18 | 2014-12-03 | Biocryst Pharm Inc | Compuestos inhibidores de la actividad de la arn polimerasa viral |
| AU2013344422A1 (en) * | 2012-11-16 | 2015-07-02 | Biocryst Pharmaceuticals, Inc. | Antiviral azasugar-containing nucleosides |
| AU2014265483B2 (en) | 2013-05-14 | 2018-08-02 | Biocryst Pharmaceuticals, Inc. | Anti-influenza compositions and methods |
| TWI678369B (zh) * | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類 |
| TWI740546B (zh) | 2014-10-29 | 2021-09-21 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
| CN104513249B (zh) * | 2014-12-26 | 2016-08-31 | 苏州明锐医药科技有限公司 | 抗埃博拉病毒药物bcx4430的制备方法 |
| SG10202109869XA (en) | 2015-09-16 | 2021-10-28 | Gilead Sciences Inc | Methods for treating arenaviridae and coronaviridae virus infections |
| US10512649B2 (en) | 2016-03-06 | 2019-12-24 | Biocryst Pharmaceuticals, Inc. | Methods and compositions for treatment of zika virus infection |
| DE102016002873A1 (de) | 2016-03-09 | 2016-05-25 | Heinz Kiefer | Zellnachweisverfahren und Screeningverfahren von Stoffbibliotheken zur Identifizierung von Einzelstoffen, die im Falle einer bioterroristischen Bedrohung gegen Mischungen synthetischer Viren wirksam sind |
| CN110869028B (zh) | 2017-03-14 | 2023-01-20 | 吉利德科学公司 | 治疗猫冠状病毒感染的方法 |
| ES2938859T3 (es) | 2017-05-01 | 2023-04-17 | Gilead Sciences Inc | Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato |
| WO2019014247A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS |
| WO2021007283A1 (en) * | 2019-07-09 | 2021-01-14 | Regents Of The University Of Minnesota | Potentiation of antiviral nucleobases as rna virus therapy |
| CN118662520A (zh) | 2020-01-27 | 2024-09-20 | 吉利德科学公司 | 用于治疗SARS CoV-2感染的方法 |
| US11613553B2 (en) | 2020-03-12 | 2023-03-28 | Gilead Sciences, Inc. | Methods of preparing 1′-cyano nucleosides |
| EP4132651B1 (en) | 2020-04-06 | 2026-03-18 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| WO2021207386A1 (en) * | 2020-04-07 | 2021-10-14 | Biocryst Pharmaceuticals, Inc. | Methods, compositions, and dosing regimens for treatment of sars-cov-2 infections |
| ES3041698T3 (en) | 2020-05-29 | 2025-11-13 | Gilead Sciences Inc | Remdesivir for the treatment of viral infections |
| EP4172160A2 (en) | 2020-06-24 | 2023-05-03 | Gilead Sciences, Inc. | 1'-cyano nucleoside analogs and uses thereof |
| HUE067491T2 (hu) | 2020-08-27 | 2024-10-28 | Gilead Sciences Inc | Vegyületek és eljárások vírusfertõzések kezelésére |
| EP4360629A4 (en) * | 2021-06-25 | 2024-11-06 | Industry Foundation of Chonnam National University | PHARMACEUTICAL COMPOSITION COMPRISING A LIPASE INHIBITOR FOR THE TREATMENT OF RNA VIRAL INFECTIONS |
| KR102871928B1 (ko) * | 2021-06-25 | 2025-10-20 | 전남대학교 산학협력단 | 지방분해효소 억제제를 포함하는 rna 바이러스 감염증 예방 또는 치료용 약제학적 조성물 |
| JP2024531898A (ja) * | 2021-08-17 | 2024-09-03 | サウスウエスト リサーチ インスティテュート | コロナウイルスに対する阻害剤 |
| CN115925640B (zh) * | 2021-08-23 | 2025-03-28 | 中国人民解放军军事科学院军事医学研究院 | ((3-氨甲酰-5-氟吡嗪-2-基)氧基)甲基异丁酸酯及其制备方法和应用 |
| US12552827B2 (en) | 2022-01-21 | 2026-02-17 | Biocryst Pharmaceuticals, Inc. | Synthesis of an antiviral azasugar triphosphate |
| AU2023227794A1 (en) | 2022-03-02 | 2024-10-17 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
| CN118359622B (zh) * | 2024-04-16 | 2025-08-26 | 上海陶术生物科技股份有限公司 | 加利司伟中间体的制备方法 |
| CN118359621B (zh) * | 2024-04-16 | 2025-05-16 | 上海陶术生物科技股份有限公司 | 加利司伟及加利司伟中间体的制备方法和相应的加利司伟中间体 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9520364D0 (en) * | 1995-10-05 | 1995-12-06 | Chiroscience Ltd | Compouundds |
| US5985848A (en) | 1997-10-14 | 1999-11-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of nucleoside metabolism |
| US6228741B1 (en) | 1998-01-13 | 2001-05-08 | Texas Instruments Incorporated | Method for trench isolation of semiconductor devices |
| US7388002B2 (en) | 2001-11-14 | 2008-06-17 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| US7098334B2 (en) | 2002-03-25 | 2006-08-29 | Industrial Research Limited | 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases |
| WO2003100009A2 (en) * | 2002-05-23 | 2003-12-04 | Biocryst Pharmaceuticals, Inc. | Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof |
| WO2006002231A1 (en) * | 2004-06-22 | 2006-01-05 | Biocryst Pharmaceuticals, Inc. | Aza nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
| CA2602533A1 (en) * | 2005-03-29 | 2006-10-05 | Biocryst Pharmaceuticals, Inc. | Use of c-nucleoside analogs for treatment of hepatitis c related viral infections |
| US20090227637A1 (en) * | 2005-12-15 | 2009-09-10 | Olaf Weber | Diaryl ureas for treating virus infections |
| CN101528749B (zh) | 2006-09-07 | 2013-07-31 | 工业研究有限公司 | 核苷磷酸化酶和水解酶的无环胺抑制剂 |
| JP2010502748A (ja) | 2006-09-11 | 2010-01-28 | サザン リサーチ インスティテュート | アゾールヌクレオシド、並びに、ｒｎａ／ｄｎａウイルスポリメラーゼ阻害剤としての使用 |
| TW200942243A (en) | 2008-03-05 | 2009-10-16 | Biocryst Pharm Inc | Antiviral therapeutic agents |
| EP2898885B1 (en) * | 2010-10-15 | 2017-11-22 | Biocryst Pharmaceuticals, Inc. | Pyrrolopyrimidine derivatives for use in the treatment of viral infections |
| WO2012063085A2 (en) * | 2010-11-11 | 2012-05-18 | Redx Pharma Limited | Drug derivatives |
| AR090699A1 (es) * | 2012-04-18 | 2014-12-03 | Biocryst Pharm Inc | Compuestos inhibidores de la actividad de la arn polimerasa viral |
-
2011
- 2011-10-14 EP EP14198125.8A patent/EP2898885B1/en active Active
- 2011-10-14 PT PT141981258T patent/PT2898885T/pt unknown
- 2011-10-14 CA CA2813783A patent/CA2813783C/en active Active
- 2011-10-14 US US13/879,110 patent/US20130331404A1/en not_active Abandoned
- 2011-10-14 RU RU2013121794/15A patent/RU2599013C2/ru active
- 2011-10-14 PT PT118335157T patent/PT2627334E/pt unknown
- 2011-10-14 PL PL14198125T patent/PL2898885T3/pl unknown
- 2011-10-14 RU RU2016134401A patent/RU2718690C2/ru active
- 2011-10-14 JP JP2013534046A patent/JP5902698B2/ja active Active
- 2011-10-14 PL PL11833515T patent/PL2627334T3/pl unknown
- 2011-10-14 HR HRP20150487TT patent/HRP20150487T1/hr unknown
- 2011-10-14 LT LTEP14198125.8T patent/LT2898885T/lt unknown
- 2011-10-14 EP EP11833515.7A patent/EP2627334B1/en active Active
- 2011-10-14 SI SI201130489T patent/SI2627334T1/sl unknown
- 2011-10-14 KR KR1020137012318A patent/KR101850925B1/ko active Active
- 2011-10-14 MX MX2013003938A patent/MX348759B/es active IP Right Grant
- 2011-10-14 WO PCT/US2011/056421 patent/WO2012051570A1/en not_active Ceased
- 2011-10-14 HU HUE14198125A patent/HUE036387T2/hu unknown
- 2011-10-14 AU AU2011315902A patent/AU2011315902B2/en active Active
- 2011-10-14 BR BR112013009029-4A patent/BR112013009029B1/pt active IP Right Grant
- 2011-10-14 CN CN201180059786.9A patent/CN103429245B/zh active Active
- 2011-10-14 EP EP17196354.9A patent/EP3345605B1/en active Active
- 2011-10-14 SM SM20180064T patent/SMT201800064T1/it unknown
- 2011-10-14 SI SI201131383T patent/SI2898885T1/en unknown
- 2011-10-14 DK DK14198125.8T patent/DK2898885T3/en active
- 2011-10-14 DK DK11833515.7T patent/DK2627334T3/en active
- 2011-10-14 ES ES11833515.7T patent/ES2536831T3/es active Active
- 2011-10-14 ES ES14198125.8T patent/ES2657687T3/es active Active
- 2011-10-14 RS RS20150369A patent/RS54072B1/sr unknown
- 2011-10-14 RS RS20180135A patent/RS56870B1/sr unknown
-
2013
- 2013-04-10 IL IL225672A patent/IL225672B/en active IP Right Grant
-
2014
- 2014-11-03 US US14/531,471 patent/US9492452B2/en active Active
-
2015
- 2015-06-25 SM SM201500148T patent/SMT201500148B/xx unknown
-
2016
- 2016-03-10 JP JP2016046875A patent/JP2016135790A/ja not_active Withdrawn
- 2016-10-28 US US15/337,320 patent/US10022375B2/en active Active
-
2017
- 2017-01-24 AU AU2017200471A patent/AU2017200471B2/en active Active
-
2018
- 2018-02-02 CY CY20181100131T patent/CY1119880T1/el unknown
- 2018-02-06 HR HRP20180220TT patent/HRP20180220T1/hr unknown
- 2018-06-20 US US16/013,059 patent/US10420769B2/en active Active
-
2019
- 2019-08-16 US US16/543,079 patent/US11173159B2/en active Active
-
2020
- 2020-03-17 RU RU2020111042A patent/RU2020111042A/ru unknown
-
2021
- 2021-10-21 US US17/506,836 patent/US12508266B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013544788A5 (enExample) | ||
| HRP20180220T1 (hr) | Derivati pirolapimiridina koji se koriste u liječenju virusnih infekcija | |
| JP2016504284A5 (enExample) | ||
| JP2015514772A5 (enExample) | ||
| Delang et al. | Favipiravir as a potential countermeasure against neglected and emerging RNA viruses | |
| RU2020116571A (ru) | N4-гидроксицитидин и производные и связанные с этим противовирусные применения | |
| NZ596014A (en) | Dihydroorotate - dehydrogenase inhibitors as virostatic compounds | |
| O'Brien et al. | Genetic factors that affect spontaneous clearance of hepatitis C or B virus, response to treatment, and disease progression | |
| WO2007103111A8 (en) | Antiviral drugs for treatment of arenavirus infection | |
| JP2009535352A5 (enExample) | ||
| JP2015517555A5 (enExample) | ||
| MX384836B (es) | Agentes antivirales contra la hepatitis b | |
| FI3981437T3 (fi) | Nukleiinihapporokotteita | |
| JP2011246469A5 (enExample) | ||
| JP2011528713A5 (enExample) | ||
| JP2009517395A5 (enExample) | ||
| JP2015517528A5 (enExample) | ||
| EA202190602A3 (ru) | 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний | |
| JP2015521156A5 (enExample) | ||
| MX2013014241A (es) | Derivados de indanona, sales farmaceuticamente aceptables o isomeros opticos de los mismos, metodo de preparacion de los mismos, y composiciones farmaceuticas que contienen los mismos como ingrediente activo para prevención o tratamiento de enfermedades virales. | |
| RU2015114543A (ru) | Способы лечения гепатита с | |
| JP2010520200A5 (enExample) | ||
| JP2010285436A5 (enExample) | ||
| JP2013503880A5 (enExample) | ||
| JP2015516419A5 (enExample) |